Saturday 17 October 2026 Export GOSS’s income statement to Excel — free account

Gossamer Bio, Inc.

Gossamer Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $48.5 million, down 57.7% from fiscal 2024. In the quarter to June 2026, revenue fell 19.6%, EPS grew 129.4%, free cash flow grew 16.3% and total debt fell 81.7%, each against the same quarter a year earlier.

8.66 0.23 −2.59%

Follow GOSS

Alert me

Market cap: $54.3M
P/E: 0.0×
Fwd P/E: −0.4×
Dividend yield: —
F-score: n/a
Altman Z: −12.52
Beneish M: 0.74
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 54.32

Revenue 53.29

Net Income (125.22)

Free Cash Flow (162.63)

Net Debt (20.88)

Current Ratio 0.53

Debt/Equity (0.38)

P/E ratio 0.00

Fwd P/E (0.36)

P/S ratio 0.65

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 73.96%

Next Y EPS Growth 32.65%

Next Y revenue growth (26.02%)

Next 5Y EPS Growth 45.71%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	296	295	137	57
Receivables	—	5	12	6
Inventory	—	—	—	—
Other	—	—	—	—
	307	310	168	73

	2023	2024	2025	Q'26
Payables	6	2	6	6
ST’ Debt	12	—	—	36
Other	—	17	20	68
	52	45	63	138

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	17	9	—	—	—
’25	10	11	13	14	48

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(39)	(39)	—	—	—
’25	(40)	(47)	(36)	(48)	(171)
’24	(52)	116	(32)	(35)	(3)
’23	(53)	(38)	(34)	(33)	(159)
’22	(53)	(49)	(37)	(48)	(187)
’21	(59)	(47)	(42)	(41)	(189)
’20	(52)	(42)	(45)	(37)	(176)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(39)	(39)	—	—	—
’25	(40)	(47)	(36)	(48)	(171)
’24	(52)	116	(32)	(35)	(3)
’23	(53)	(38)	(34)	(33)	(159)
’22	(54)	(49)	(37)	(48)	(187)
’21	(60)	(48)	(43)	(41)	(190)
’20	(53)	(43)	(45)	(37)	(178)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(16.00)	4.11	—	—	—
’25	(12.80)	(13.60)	(16.80)	(16.80)	(60.00)
’24	(15.20)	17.60	(11.20)	(12.00)	(20.00)
’23	(41.60)	(36.00)	(16.80)	(16.80)	(94.40)
’22	(60.80)	(59.20)	(52.00)	(47.20)	(216.80)
’21	(62.40)	(64.00)	(64.00)	(59.20)	(250.40)
’20	(69.60)	(80.00)	(64.00)	(70.40)	(284.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	1,132.80	601.60	563.20	125.60	36.24	39.92	60.80	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	2,172.00	1,343.20	1,144.00	1,215.60	244.80	128.00	309.60
People
People	Employees	—	105	119	171	196	185	178	135	145	162
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.79	0.30
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	115	48
	Gross margin, %	—	—	0.00	0.00	0.00	0.00	0.00	—	100.00	100.00
	EBT	0	(7)	(147)	(180)	(243)	(234)	(229)	(180)	(56)	(170)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(48.50)	(351.67)
	Net income	0	(7)	(147)	(180)	(243)	(234)	(229)	(180)	(57)	(170)
	Depreciation	—	—	0	1	8	12	4	(4)	(8)	(5)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	40.56	16.97
	Earnings	0.00	(59.13)	(1,807.20)	(263.20)	(284.00)	(250.40)	(216.80)	(94.40)	(20.00)	(60.00)
	Cash flow	0.00	(50.17)	(627.85)	(211.65)	(205.93)	(201.91)	(176.91)	(83.42)	(1.23)	(59.96)
	Capex	0.00	0.00	(42.93)	(4.33)	(1.75)	(1.65)	(0.39)	0.00	0.00	(0.03)
	Free cash flow	0.00	(50.17)	(670.77)	(215.99)	(207.69)	(203.57)	(177.30)	(83.42)	(1.23)	(59.98)
	Book value	0.00	(59.93)	(1,476.86)	515.10	374.46	129.84	11.42	32.90	10.43	(42.98)
	Shares, m	66	0	0	1	1	1	1	2	3	3
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	0.00	0.00
	P/S	—	—	—	—	—	—	—	—	0.00	14.62
	P/B	—	—	—	—	—	—	—	—	6.94	0.00
	EV/Sales	—	—	—	—	—	—	—	—	0.00	16.08
	EV/FCF	—	—	—	—	—	—	—	—	(30.26)	(4.55)
Cash, $m
Cash, $m	Operating cash flow	0	(6)	(51)	(145)	(176)	(189)	(187)	(159)	(3)	(171)
	Capex	—	—	(3)	(3)	(2)	(2)	0	—	—	0
	Free cash flow	0	(6)	(55)	(148)	(178)	(190)	(187)	(159)	(3)	(171)
Balance, $m
Balance, $m	Working capital	0	(1)	212	372	484	292	213	255	265	104
	Total debt	0	6	—	31	176	182	219	209	198	199
	Net debt	0	6	(229)	(371)	(337)	(143)	(36)	(87)	(97)	62
	Shareholders’ equity	—	(7)	(120)	352	321	121	12	63	29	(123)
Returns, %
Returns, %	ROA	(37.30)	(3,043.15)	(122.54)	(54.14)	(50.38)	(53.00)	(74.46)	(61.54)	(18.03)	(69.89)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	2.38	193.87	231.57	(155.16)	(72.30)	(105.85)	(343.53)	(480.50)	(122.54)	365.33

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TENX Tenax Therapeutics, Inc.	$56.5M	— (loss-making)	—	−77.98% (below 0%: shrinking)	n/m	−125.93% (below 0%: shrinking)	0.00%	0.00%	Compare
ALPS Alps Group Inc.	$56.4M	— (loss-making)	—	—	n/m	−26.48% (below 0%: shrinking)	—	0.00%	Compare
ELOX Senesco Technologies Inc.	$55.3M	— (loss-making)	—	—	n/m	−144.34% (below 0%: shrinking)	100.00%	0.00%	Compare
GUTS Fractyl Health, Inc.	$55.2M	— (loss-making)	— (loss-making)	−57.14% (below 0%: shrinking)	n/m	+25.34% (above 0%: growing)	100.00%	0.00%	Compare
GOSS Gossamer Bio, Inc.	$54.3M	— (loss-making)	— (loss-making)	−19.59% (below 0%: shrinking)	n/m	+16.32% (above 0%: growing)	100.00%	(282.25%)
RNTX Rein Therapeutics Inc.	$54.2M	— (loss-making)	—	—	n/m	−34.62% (below 0%: shrinking)	0.00%	0.00%	Compare
RNXT RenovoRx, Inc.	$53.7M	— (loss-making)	— (loss-making)	+115.40% (above 0%: growing)	n/m	−27.63% (below 0%: shrinking)	84.27%	(368.43%)	Compare
BOLD Boundless Bio, Inc.	$53.5M	— (loss-making)	—	—	n/m	−76.90% (below 0%: shrinking)	—	0.00%	Compare
ATHE Alterity Therapeutics Limited - Sponsored ADR	$52.0M	— (loss-making)	—	—	0.00%	−84.83% (below 0%: shrinking)	0.00%	—	Compare
Median of peers	$54.7M	—	—	−57.14%	—	−55.76%	42.14%	0.00%

All 614 Biotechnology stocks →

Gossamer Bio, Inc. (GOSS) key facts

Concern: Gossamer Bio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $48.5 million, down 57.7% from fiscal 2024.
Gossamer Bio, Inc. (GOSS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, GOSS traded at $8.66, a market capitalization of $54.3 million.
Return on equity was 365.3% and debt-to-equity -0.38.
Its Altman Z-score is −12.52 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.